Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.21.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance, beginning at Dec. 31, 2018 $ (21,708)   $ 37 $ 149,682 $ (69) $ (171,358)  
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018   $ (29)         $ (29)
Balance, beginning (in shares) at Dec. 31, 2018     37,341,393        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Beneficial conversion feature relating to convertible notes payable 8,765     8,765      
Common stock issued for cash (net of issuance cost) 8,589   $ 2 8,587      
Common stock issued for cash (net of issuance cost) (in shares)     1,677,013        
Common stock issued in merger (1,645)   $ 2 (1,647)      
Common stock issued in merger ( in shares)     2,330,548        
Conversion of convertible notes payable and notes payable to common stock 39,499   $ 7 39,492      
Conversion of convertible notes payable and notes payable to common stock (in shares)     7,068,760        
Exercise of stock options 1     1      
Exercise of stock options (in shares)     175        
Exercise of warrants 186     186      
Exercise of warrants (in Shares)     53,557        
Warrant and conversion feature reclassified to equity 6,336     6,336      
Fair value of replacement equity awards 2,438     2,438      
Foreign currency translation effect (10)       (10)    
Share-based compensation 1,367     1,367      
Net income (loss) (54,842)         (54,842)  
Balance, ending at Dec. 31, 2019 (11,053)   $ 48 215,207 (79) (226,229)  
Balance, ending (in shares) at Dec. 31, 2019     48,471,446        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Common stock issued for cash (net of issuance cost) 142   $ 1 141      
Common stock issued for cash (net of issuance cost) (in shares)     515,743        
Fair value of warrants including down-round protection adjustments 2,437     2,641   (204)  
Unrealized gain on debt securities available for sale (net of tax) 1,280       1,280    
Foreign currency translation effect (57)       (57)    
Share-based compensation 739     739      
Net income (loss) 1,354         1,354  
Balance, ending at Dec. 31, 2020 $ (5,158)   $ 49 $ 218,728 $ 1,144 $ (225,079)  
Balance, ending (in shares) at Dec. 31, 2020     48,987,189